For adults with chronic hepatitis C virus (HCV) infection, direct-acting antivirals are associated with a reduced risk for mortality and hepatocellular carcinoma, according to a study published online February 11 in The Lancet.
The Food and Drug Administration (FDA) has approved a labeling update for Vemlidy (tenofovir alafenamide; Gilead Sciences) to include dosage information regarding its use in adults with end-stage renal disease (ESRD; CrCl <15mL/min) who are receiving chronic hemodialysis.
The information, posted to the Food and Drug Administration (FDA) website, states that both the Recombivax HB adult (10mcg/mL) and dialysis (40mcg/mL) formulations are not expected to be available in 2019.
Due to the limited amount of published literature analyzing treatment options for older chronic HCV infection patients, the study authors aimed to determine the efficacy and tolerability of glecaprevir/pibrentasvir in this population.
The Indication section has been revised to state that Viread is intended for use in the treatment of chronic hepatitis B in adults and pediatric patients 2 years of age and older weighing at least 10kg.
In order to determine the association between CHC and parkinsonism, the study authors utilized the National Health Insurance Research Database in Taiwan to identify CHC patients between 2004 and 2012.
The study, which was an open multi-cohort Markov model, aimed to analyze the clinical and economic outcomes of the United States HCV population from 2018 on.
The retrospective study aimed to determine the risk of incident, or de novo, HCC following different regimens of antiviral therapy.
The review analyzed 168 patients treated with an oral DAA at a single center from 2015 to 2017.
The study utilized data from the Chronic Hepatitis Cohort Study, an observational cohort study, to assess demographic and clinical characteristics associated with DAA use.
